These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21114824)

  • 1. Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA).
    Pettersson B; Ambegaonkar B; Sazonov V; Martinell M; Stålhammar J; Wändell P
    BMC Public Health; 2010 Nov; 10():737. PubMed ID: 21114824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
    Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
    Stacy TA; Egger A
    J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.
    Ambegaonkar BM; Bash LD; Chirovsky DR; Jameson K; Grant S; Nocea G; Pettersson B; Sazonov V
    Eur J Intern Med; 2013 Oct; 24(7):656-63. PubMed ID: 23953848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering therapy and lipid goal attainment in patients with metabolic syndrome in China: subgroup analysis of the Dyslipidemia International Study-China (DYSIS-China).
    Wang F; Ye P; Hu D; Min Y; Zhao S; Wang Y; Mu Y; Yan X; Li Z; Wei Y; Li J;
    Atherosclerosis; 2014 Nov; 237(1):99-105. PubMed ID: 25238215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study.
    Khovidhunkit W; Silaruks S; Chaithiraphan V; Ongphiphadhanakul B; Sritara P; Nimitphong H; Benjanuwattra T; Ambegaonkar BM
    Angiology; 2012 Oct; 63(7):528-34. PubMed ID: 22222187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries.
    Unniachan S; Bash LD; Khovidhunkit W; Sri RZ; Vicaldo E; Recto C; Ambegaonkar BM
    Int J Clin Pract; 2014 Aug; 68(8):1010-9. PubMed ID: 24666791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong.
    Ambegaonkar B; Chirovsky D; Tse HF; Lau YK; Tomlinson B; Li SK; Yue CS; Wong TH; Choi MC; Tunggal P; Sazonov V
    Adv Ther; 2012 May; 29(5):427-41. PubMed ID: 22562782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.
    Kristensen MS; Green A; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Larsen ML; Ersbøll AK
    BMC Cardiovasc Disord; 2020 Jul; 20(1):336. PubMed ID: 32660429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.
    Nag SS; Daniel GW; Bullano MF; Kamal-Bahl S; Sajjan SG; Hu H; Alexander C
    J Manag Care Pharm; 2007 Oct; 13(8):652-63. PubMed ID: 17970603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
    Tóth PP; Potter D; Ming EE
    J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe.
    Ferrieres J; De Ferrari GM; Hermans MP; Elisaf M; Toth PP; Horack M; Brudi P; Lautsch D; Bash LD; Baxter CA; Ashton V; Ambegaonkar B; Gitt AK
    Eur J Prev Cardiol; 2018 Dec; 25(18):1966-1976. PubMed ID: 30335504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.
    Ferrières J; Rouyer MV; Lautsch D; Ashton V; Ambegaonkar BM; Brudi P; Gitt AK;
    Arch Cardiovasc Dis; 2017 Mar; 110(3):167-178. PubMed ID: 28209375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany.
    Gitt AK; Jünger C; Smolka W; Bestehorn K
    Clin Res Cardiol; 2010 Nov; 99(11):723-33. PubMed ID: 20521058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy.
    Colquhoun D; Chirovsky D; Sazonov V; Cui YA; Ambegaonkar B
    Exp Clin Cardiol; 2013; 18(1):e32-6. PubMed ID: 24294045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attainment of goal and normalized lipid levels with lipid-modifying therapy in Malaysia.
    Hsu TY; Chirovsky D; Moy FM; Ambegaonkar BM
    Clin Ther; 2013 Apr; 35(4):450-60. PubMed ID: 23481458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.
    Jones PH; Nair R; Thakker KM
    J Am Heart Assoc; 2012 Dec; 1(6):e001800. PubMed ID: 23316314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.